23384-72-7

Usage

Uses

Used in Pharmaceutical Industry:
3',4'-Difluoropropiophenone is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique structure and reactivity make it a valuable intermediate in the development of new drugs and organic molecules, contributing to the advancement of medicinal chemistry.
Used in Organic Chemistry:
In the field of organic chemistry, 3',4'-Difluoropropiophenone serves as a versatile intermediate for the synthesis of a wide range of organic compounds. Its fluorinated nature allows for the creation of novel molecules with distinct properties, expanding the scope of organic synthesis and the potential applications of the resulting compounds.

InChI:InChI=1/C9H8F2O/c1-2-9(12)6-3-4-7(10)8(11)5-6/h3-5H,2H2,1H3

Upstream product

• 367-11-3 ortho-difluorobenzene 
• 79-03-8 propionyl chloride 
• 369-33-5 3',4'-difluoroacetophenone 
• 68-12-2 N,N-dimethyl-formamide 
• 34036-07-2 3,4 difluorobenzaldehyde 

Downstream Products

• 1217255-04-3 1-(3,4-difluoro-phenyl)-propan-1-one oxime 
• 1415763-95-9 1-(3,4-difluorophenyl)-1-oxopropan-2-yl 4-methylbenzenesulfonate 
• 1428228-50-5 C₁₈H₁₆F₂N₄O 
• 1428229-04-2 C₁₄H₁₄F₂N₂O₂ 
• 1428228-97-0 C₁₃H₁₂F₂O₄ 
• 309720-84-1 1-(3-fluoro-4-morpholinophenyl)propan-1-one 

Relevant academic research and scientific papers

Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors

Viral infections are increasing and probably long-lasting global risks. In this study, a chemical library was exploited by phenotypic screening to discover new antiviral inhibitors. After optimizations from hit to lead, a novel potent small molecule (RYL-634) was identified, showing excellent broad-spectrum inhibition activity against various pathogenic viruses, including hepatitis C virus, dengue virus, Zika virus, chikungunya virus, enterovirus 71, human immunodeficiency virus, respiratory syncytial virus, and others. The mechanism of action and potential targets of RYL-634 were further explored by the combination of activity-based protein profiling and other techniques. Finally, human dihydroorotate dehydrogenase was validated as the major target of RYL-634. We did not observe any mutant resistance under our pressure selections with RYL-634, and it had a strong synergistic effect with some Food and Drug Administration-approved drugs. Hence, there is great potential for developing new broad-spectrum antivirals based on RYL-634.

DMF as carbon source: Rh-catalyzed α-methylation of ketones

An unprecedented Rh-catalyzed direct methylation of ketones with N,N-dimethylformamide (DMF) is disclosed. The reaction shows a broad substrate scope, tolerating both aryl and alkyl ketones with various substituents. Mechanistic studies suggest that DMF delivers a methylene fragment followed by a hydride in the methylation process.

Combination therapy for the treatment of benign prostatic hyperplasia

This invention relates to combination therapy for the treatment of benign prostatic hyperplasia comprising an alpha-1a antagonist and an endothelin antagonist. More specifically, the use of a selective alpha-1a adrenergic receptor antagonist in combination with a subtype non-selective endothelin antagonist provides relief of lower urinary tract symptoms in patients with symptomatic prostatism or benign prostatic hyperplasia. This combination therapy improves lower urinary tract symptoms including increasing urine flow rate, decreasing residual urine volume and improving overall obstructive and irritative symptoms in patients with benign prostatic hyperplasia or symptomatic prostatism.

Oxazolidinones as alpha 1A receptor antagonists

This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.